About

The HealthPartners Institute Cancer Research Center (CRC) delivers the latest oncology research services typically found only at leading academic health care institutions. With a strong focus on quick responsiveness and rapid turnaround, the CRC maintains an active pipeline of phase I through phase III clinical trials, and investigator-initiated studies, consistently approving 3-4 new studies each month. Our mission is to benefit patients through innovative cancer care that integrates clinical research and quality improvement into routine care—close to home.

Our systemwide cancer centers also participate in the Metro Minnesota Community Oncology Consortium (MMCORC), a nonprofit research program sponsored by the National Cancer Institute (NCI).  MMCORC’s mission is to provide the opportunity for patients to enroll in a high-quality clinical trial for the treatment or prevention of cancer in their own community while being treated by a local physician. Two of our HealthPartners Cancer Centers (HealthPartners Cancer Center at Regions Hospital and HealthPartners Frauenshuh Cancer Center) are the top accruing sites for the consortium, which recently received the platinum level award from NCI for high enrollment. 

HealthPartners Cancer Care includes approximately 40 medical oncologists geographically distributed across the Twin Cities. Our medical oncologists are trained in hematology/oncology and support our clinical research by serving as sub-investigators on trials, reviewing incoming trial opportunities, and developing novel clinical research questions. Listed below are the clinician investigators who serve as principal investigators on our trials.

Affiliation
people
Faculty Position
  • Anderson, Daniel M., MD, MPH, Principal Investigator, Metro-Minnesota Community Oncology Research Consortium 2003 -
  • Demel, Kurt C., MD, MBA, Core Investigator, Cancer Research Center and Investigator, Metro-Minnesota Community Oncology Research Consortium 2022 -
  • Ji, Yan, MD, PhD, MS, Co-Principal Investigator, Metro-Minnesota Community Oncology Research Consortium 2016 -
  • Larson, Timothy G., MD, MS, Medical Director, Early Phase Therapeutics Program, Cancer Research Center and Investigator, Metro-Minnesota Community Oncology Research Consortium 2022 -
  • Lerner, Rachel E., MD, MS, Core Investigator, Cancer Research Center and Investigator, Metro-Minnesota Community Oncology Research Consortium 2013 -
  • Phillips, Kester A., MD, Core Investigator, Cancer Research Center and Investigator, Metro-Minnesota Community Oncology Research Consortium 2023 -
  • Ruan, Gordon J., MD, Core Investigator, Cancer Research Center and Investigator, Metro-Minnesota Community Oncology Research Consortium 2025 -
  • Vijayakumar, Jayanthi, MBBS, Core Investigator, Cancer Research Center and Investigator, Metro-Minnesota Community Oncology Research Consortium 2020 -
  • Zylla, Dylan M., MD, MS, Medical Director, Cancer Research Center and Investigator, Metro-Minnesota Community Oncology Research Consortium 2019 -
  • Publications While At HealthPartners
    selected publications
    Journal Article
  • A randomized, open-label trial to assess feasibility and tolerability of topical cannabis balms for the treatment of aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). 
    Cannabis and cannabinoid research. 2026
  • Engendering reproductive health within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11. 
    JCO Oncol Pract. 2026
  • Epidemiology of Erdheim-Chester disease in the United States: a SEER-based analysis. 
    Blood Neoplasia. 2026
  • Impact of comorbidities on clinical outcomes and quality of life of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer treated with Palbociclib in the POLARIS Study. 
    Cancer medicine. 2026
  • The difficulty in validating cannabis anticancer claims [letter]. 
    Cannabis and cannabinoid research. 2026
  • A first-in-human study of the SUMOylation Inhibitor Subasumstat in patients with advanced/metastatic solid tumors or relapsed/refractory hematologic malignancies. 
    Cancer Res Commun. 2025
  • Association of financial wellness with patterns of medical cannabis use and patient-reported outcomes in adults with cancer. 
    Cannabis (Research Society on Marijuana). 2025
  • Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes. 
    Blood advances. 2025
  • Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis. 
    Cancer Immunology, Immunotherapy. 2025
  • Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants. 
    Leukemia. 2025
  • Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials. 
    Cancer. 2025
  • Final report on NCCTG N0877 (Alliance): a phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma. 
    Neuro-Oncology. 2025
  • Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival. 
    Experimental hematology & oncology. 2025
  • PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms. 
    Leukemia and Lymphoma. 2025
  • Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. 
    The oncologist. 2025
  • Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS. 
    Future Oncology (London, England). 2025
  • Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. 
    Nature Medicine. 2025
  • Data quality in a survey of registered medical cannabis users with cancer: nonresponse and measurement error. 
    Journal of the National Cancer Institute. Monographs. 2024
  • Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma. 
    The oncologist. 2024
  • PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). 
    Journal of Clinical Oncology. 2024
  • Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers. 
    Journal of the National Cancer Institute. Monographs. 2024
  • Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL. 
    Blood. 2024
  • An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. 
    Investigational New Drugs. 2023
  • Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. 
    Commun Med (Lond). 2023
  • The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma. 
    Melanoma Research. 2023
  • Validation of immunotherapy response score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit. 
    Cancer Res Commun. 2023
  • Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial. 
    JAMA. 2022
  • Holy smokes! Developing a cannabis clinic for patients with cancer. 
    Oncol Issues. 2022
  • Organizational characteristics and smoking cessation support in community-based lung cancer screening programs. 
    Journal of the American College of Radiology. 2022
  • Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216). 
    Journal of Clinical Oncology. 2022
  • A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. 
    Supportive Care in Cancer. 2021
  • Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. 
    Lancet Oncology. 2021
  • Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. 
    European Journal of Cancer. 2021
  • Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples. 
    JCO precision oncology. 2021
  • A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: the MAESTRO study. 
    Cancer. 2020
  • Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. 
    Journal of Thrombosis and Haemostasis. 2020
  • Collection of electronic patient-reported symptoms in patients with advanced cancer using Epic MyChart surveys. 
    Supportive Care in Cancer. 2020
  • Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer. 
    American Journal of Clinical Oncology. 2020
  • Multisite, randomized trial of early integrated palliative and oncology care in patients with advanced lung and gastrointestinal cancer: Alliance A221303. 
    Journal of Palliative Medicine. 2020
  • Performance measures based on how adults with cancer feel and function: stakeholder recommendations and feasibility testing in six cancer centers. 
    JCO Oncol Pract. 2020
  • Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. 
    Journal of Clinical Oncology. 2020
  • Sequencing ipilimumab immunotherapy before or after chemotherapy (nab-paclitaxel and bevacizumab) for the treatment of BRAFwt (BRAF wild-type) metastatic malignant melanoma: results of a study of Academic and Community Cancer Research United (ACCRU) RU261206I. 
    American Journal of Clinical Oncology. 2020
  • A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. 
    Cancer. 2019
  • Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. 
    Journal of Diabetes and Its Complications. 2019
  • Impact of medical cannabis on patient-reported symptoms for patients with cancer enrolled in Minnesota's Medical Cannabis Program. 
    Journal of Oncology Practice. 2019
  • Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. 
    New England Journal of Medicine. 2018
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 
    Lancet Oncology. 2018
  • Impact of opioid use on health care utilization and survival in patients with newly diagnosed stage IV malignancies. 
    Supportive Care in Cancer. 2018
  • Oncology clinicians and the Minnesota Medical Cannabis Program: a survey on medical cannabis practice patterns, barriers to enrollment, and educational needs. 
    Cannabis and cannabinoid research. 2018
  • Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. 
    Blood. 2018
  • Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. 
    New England Journal of Medicine. 2017
  • Establishment of personalized pain goals in oncology patients to improve care and decrease costs. 
    Journal of Oncology Practice. 2017
  • Providing breast cancer survivorship: lessons learned from a pilot project implementation. 
    Cancer Nursing. 2017
  • The financial toll of cancer therapy: developing ways to help the patient. 
    Minn Physician. 2017
  • Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. 
    Lancet Oncology. 2016
  • Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. 
    Annals of Oncology. 2016
  • Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). 
    Breast Cancer Research and Treatment. 2016
  • A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. 
    American Journal of Hematology. 2015
  • North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. 
    Menopause (New York, N.Y.). 2015
  • Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. 
    British Journal of Anaesthesia. 2014
  • NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. 
    Journal of Thoracic Oncology. 2014
  • Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. 
    Cancer. 2013
  • N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. 
    Annals of Oncology. 2010
  • Impact of chemotherapy in women with metastatic breast cancer diagnosed 1990-2003. 
    Clinical Breast Cancer. 2007
  • Editorial Article
  • Challenges for clinical cannabis and cannabinoid research in the United States [editorial]. 
    Supportive Care in Cancer.  30. 2022
  • Chapter
  • Cannabis and cannabinoids in integrative oncology. 
    Comprehensive integrative oncology. 2026
  • Conference Poster
  • Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy [poster]
    2018
  • Incidence of diabetes and hyperglycemia among patients receiving glucocorticoids with chemotherapy [poster]
    2018
  • Psychological and spiritual well being of breast cancer survivors in a community-based cancer survivorship clinic [poster]
    2010
  • Statin use is associated with a reduced risk of colon cancer recurrence [poster]
    2008
  • Statin use is associated with a reduced risk of colon cancer recurrence [poster]
    2008
  • Impact of chemotherapy in women with metastatic breast cancer diagnosed between 1990 and the present [poster]
    2005
  • Review
  • Effective strategies for the prevention and mitigation of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia: optimizing patient care [review]. 
    Clinical Breast Cancer. 2025
  • The impact of cannabis on immune checkpoint inhibitor therapy: a systematic review of immunomodulatory effects of cannabis in patients with and without cancer [systematic review, review]. 
    Supportive Care in Cancer. 2025
  • Cannabis as an anticancer agent: a review of clinical data and assessment of case reports [review]. 
    Cannabis and cannabinoid research. 2022
  • A comprehensive review of cannabis in patients with cancer: availability in the USA, general efficacy, and safety [review]. 
    Current Oncology Reports. 2019
  • A systematic review of the impact of pain on overall survival in patients with cancer [review, systematic review]. 
    Supportive Care in Cancer. 2017
  • Abstract
  • A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS) [abstract]. 
    Journal of Clinical Oncology. 2024
  • Cannabis use for cancer-related symptoms in rural versus urban Minnesota [abstract]. 
    Journal of Clinical Oncology. 2024
  • A novel cannabis education clinic for patients with cancer: patient characteristics from initial visit [abstract]. 
    Journal of Clinical Oncology. 2022
  • Self-reported efficacy and usage of cannabis among patients with cancer within the Minnesota Cannabis Program [abstract]. 
    Journal of Clinical Oncology. 2022
  • Medical scribes in a community oncology clinic [abstract]. 
    Journal of Clinical Oncology. 2016
  • A randomized trial of vitamin D3 in aromatase inhibitor-associated musculoskeletal symptoms [abstract]. 
    Journal of Clinical Oncology. 2015
  • Vitamin D3 supplementation, musculoskeletal (MS) symptoms and aromatase inhibitor [abstract]. 
    Cancer Research. 2013
  • Audio Document
  • Overcoming cannabis research barriers in oncology [podcast]
    2025
  • Quick Info